Nilotinib dihydrochloride dihydrate is the clinically used salt form of nilotinib, a tyrosine kinase inhibitor (TKI). It is mainly used to treat Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in both chronic and accelerated phases. This form enhances the stability, solubility, and bioavailability of nilotinib for oral administration. Like the base compound, it works by selectively inhibiting the BCR-ABL fusion protein, helping to control the proliferation of malignant white blood cells. It is grouped under the following drug class(es): Antineoplastic agents. Its therapeutic use is listed as antineoplastics. The directory classifies it as a unknown/inactive API with a synthetic source/manufacturing origin. Other names for this substance include Benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, hydrochloride and hydrate (1:2:2). Its PubChem CID is 50990967.
Nilotinib dihydrochloride dihydrate
| CAS No | 1277165-20-4 |
|---|---|
| Molecular Formula | C28H28Cl2F3N7O3 |
| Molecular Weight | 638.5 g/mol |
| Synonyms | 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide;dihydrate;dihydrochloride |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Nilotinib dihydrochloride dihydrate is the clinically used salt form of nilotinib, a tyrosine kinase inhibitor (TKI). It is mainly used to treat Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in both chronic and accelerated phases.
The listed CAS number is 1277165-20-4.
The listed molecular formula is C28H28Cl2F3N7O3.
The listed molecular weight is 638.5 g/mol.
4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide;dihydrate;dihydrochloride.
The source lists Benzamide, 4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-(3-pyridinyl)-2-pyrimidinyl)amino)-, hydrochloride and hydrate (1:2:2).